Pfizer and BioNTech said on Friday that a committee from the European Medicine Agency recommended marketing authorization for its Omicron adapted vaccine to prevent Covid-19, meaning the vaccine is ...
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...
For those wanting the home test kit, free rapid antigen tests will continue to be available through local public health units ...
Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...
The XBB.1.5 subvariant — nicknamed ‘Kraken’ — is arguably the most genetically rich and most transmissible SARS-CoV-2 omicron subvariant yet. News Wrap: Russia shells Bakhmut in eastern ...
The following is a summary of “A two-variant model of SARS-COV-2 transmission: estimating the characteristics of a newly emerging strain,” published in the September 2024 issue of Infectious Diseases ...
Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European Medicines Agency’s (EMA) CHMP for use in individuals aged six months and older.
Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use ...
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted ...
The winter season ushers in a new globally spreading COVID-19 variant called XEC, a mix of KS.1.1 and KP.3.3, both from the ...
Invivyd Inc. beat a shareholder lawsuit alleging the biopharma company misled shareholders with optimistic projections about the effectiveness of its Covid-19 treatment against the omicron variant.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback